- Immunization:
- Adults & >2years: SC/IM 0.5mL*1
- Children with pneumococcal 13-valent conjugate:
- 6 weeks-6 months: IM 0.5mL every 4-8 weeks *3 doses, then 0.5mL *1 at month 12-15 and at least 8 weeks after prior dose
- 7-11 months: IM 0.5mL *2 doses at least 4 weeks apart, then 0.5mL *1 when patient is >1 year old and at least 8 weeks after prior dose
- 12-23 months: IM 0.5mL *2 doses at least 8 weeks apart
- Injection:
- Purified preparations of pneumococcal capsular polysaccharide of valent 13, 15, 20 or 23
- Given IM preferably in the anterolateral aspect of the thigh in infants or the deltoid muscle in children and adults.
- May be given SC to patients with thrombocytopenia or coagulation disorder if the potential benefit outweighs the risks
Bacterial inactivated vaccine
Exact mechanism unknown. It induces antibody formation
- Injection site reaction
- Irritability
- Altered sleep patterns
- Fatigue
- Headache
- Loss of appetite
- Musculoskeletal pain
- Rigors
- Fever
- Rash
- Vomiting
- Diarrhea
- Children under 6 weeks
- Severe febrile conditions
- Hypersensitivity to diphtheria toxoid
None restricted
Drug Status
| Availability | Prescription only |
| Pregnancy | Weigh risk vs benefit |
| Breastfeeding | Can be used |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Pneumovax 23 | FDC | Pre-Filled Syringe | 1D | Merck Ltd | Laborex Kenya |
| Prevenar 13 | FDC | Injection | 1D, 10D | Pfizer Labs | Pfizer Labs |
| Synflorix | FDC | Pre-Filled Syringe | 1D | GSK Ltd | GSK Ltd |